Richard Thomas Maziarz, MD discusses the JULIET trial at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. Chimeric antigen receptor T-cell therapy with tisagenlecleucel induced durable responses among pretreated adults with relapsed or refractory diffuse large B-cell lymphoma, according to 19-month follow-up results from the phase 2 JULIET trial.

Researchers observed efficacy across all subgroups, including elderly patients and those with clinical or biological factors typically associated with poorer prognosis after receipt of other available treatments.

Kymriah (tisagenlecleucel, Novartis) is an anti-CD19 CAR T-cell therapy approved for treatment of patients aged 25 years or younger with B-cell precursor acute lymphoblastic leukemia that is refractory or in second relapse. The agent also is approved for treatment of patients with DLBCL, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma who received two or more lines of systemic therapy.